unknown
Stage
2
Investors
About
Xspray Pharma develops improved amorphous formulations of marketed drugs, primarily protein kinase inhibitors (PKIs), using a patented spray-drying technology to create product candidates for oncology. The company aims to offer formulation variants that can enter market after original drug substance patents expire and that retain patient-beneficial properties versus generic crystalline forms.
Explore Xspray Pharma's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.